ITOS vs. WVE, GYRE, PAHC, MLYS, COLL, SNDX, RCUS, ELVN, AVDL, and SYRE
Should you be buying iTeos Therapeutics stock or one of its competitors? The main competitors of iTeos Therapeutics include Wave Life Sciences (WVE), Gyre Therapeutics (GYRE), Phibro Animal Health (PAHC), Mineralys Therapeutics (MLYS), Collegium Pharmaceutical (COLL), Syndax Pharmaceuticals (SNDX), Arcus Biosciences (RCUS), Enliven Therapeutics (ELVN), Avadel Pharmaceuticals (AVDL), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.
iTeos Therapeutics vs.
Wave Life Sciences (NASDAQ:WVE) and iTeos Therapeutics (NASDAQ:ITOS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk, institutional ownership and community ranking.
In the previous week, iTeos Therapeutics had 18 more articles in the media than Wave Life Sciences. MarketBeat recorded 30 mentions for iTeos Therapeutics and 12 mentions for Wave Life Sciences. Wave Life Sciences' average media sentiment score of 1.15 beat iTeos Therapeutics' score of 0.45 indicating that Wave Life Sciences is being referred to more favorably in the media.
Wave Life Sciences presently has a consensus target price of $21.17, indicating a potential upside of 250.44%. iTeos Therapeutics has a consensus target price of $17.86, indicating a potential upside of 117.24%. Given Wave Life Sciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Wave Life Sciences is more favorable than iTeos Therapeutics.
Wave Life Sciences received 319 more outperform votes than iTeos Therapeutics when rated by MarketBeat users. However, 75.38% of users gave iTeos Therapeutics an outperform vote while only 67.77% of users gave Wave Life Sciences an outperform vote.
89.7% of Wave Life Sciences shares are owned by institutional investors. Comparatively, 97.2% of iTeos Therapeutics shares are owned by institutional investors. 29.1% of Wave Life Sciences shares are owned by company insiders. Comparatively, 12.5% of iTeos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Wave Life Sciences has higher revenue and earnings than iTeos Therapeutics. Wave Life Sciences is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Wave Life Sciences has a beta of -0.92, meaning that its stock price is 192% less volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500.
iTeos Therapeutics has a net margin of 0.00% compared to Wave Life Sciences' net margin of -66.50%. iTeos Therapeutics' return on equity of -20.11% beat Wave Life Sciences' return on equity.
Summary
Wave Life Sciences beats iTeos Therapeutics on 10 of the 19 factors compared between the two stocks.
Get iTeos Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
iTeos Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ITOS) was last updated on 5/22/2025 by MarketBeat.com Staff
